Nicholas Jacobus

Pharmaceutical collaborations expand as Flagship Pioneering expands its partnership with GSK, signing agreements with ProFound Therapeutics and Quotient Therapeutics, while Valo Health teams up with Merck KGaA to tackle disease challenges.

In today’s Pharmaceutical Executive Daily, learn how Moderna is expanding its manufacturing footprint in Massachusetts, GSK is advancing new research collaborations under the LTZ Fleming Initiative, and the FDA commissioner highlights how early and late movers can benefit from the National Priority Voucher program.

The FDA approves multiple new drugs, enhancing treatment options for cancer and other conditions.

Abbott's acquisition of Exact Sciences enhances cancer diagnostics and expands access to innovative screening and treatment solutions for patients worldwide.

In today’s Pharmaceutical Executive Daily, learn how Novo Nordisk is launching an introductory offer for Wegovy and Ozempic, AbbVie and Genmab gain FDA approval for Epkinly in follicular lymphoma, and Johnson & Johnson announces a $3 billion definitive agreement to acquire Halda Therapeutics.

GSK's collaborations leverage cutting-edge technology and scientific expertise to advance and accelerate research.

Moderna invests $140 million in its Norwood facility, creating hundreds of bio jobs while also enhancing manufacturing presence in the U.S.

Avadel Pharmaceuticals accepted Alkermes enhanced acquisition proposal for $2.3 billion, focusing on a key treatment's approval for added value.

Johnson & Johnson aims to enhance its oncology portfolio and innovate prostate cancer treatments by expanding its therapeutic pipeline through the acquisition.

In today’s pharmaceutical executive daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli Lilly, and the FDA launches its new Plausible Mechanism Pathway to accelerate drug development.

UnitedHealth Group appoints Dr. Scott Gottlieb to its board, enhancing leadership amongst a time in which the company looks to enhance its public outlook.

Eli Lilly partners with ABL Bio to research innovative therapeutics and expand its portfolio in cancer and CNS diseases through advanced bispecific antibody technology.

Jay Lalezari, CEO, CytoDyn, emphasizes how regulatory T cells play a crucial role in tumor progression by enabling cancers to evade immune detection.

In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA unveils a new Plausible Mechanism Pathway to accelerate drug reviews, and Ovid Therapeutics and Metagenomi share key third-quarter results and leadership changes.

Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its dual role in promoting tumor cell migration and shaping a protective tumor microenvironment.

In today’s Pharmaceutical Executive Daily, Richard Pazdur is named director of FDA’s Center for Drug Evaluation and Research, Pfizer strengthens focus through strategic partnerships and spin-offs, and CMS launches a new initiative to reduce Medicaid drug costs.

FDA introduces a new drug approval process, the Plausible Mechanism Pathway, streamlining drug approvals for personalized therapies targeting rare genetic diseases without traditional trials.

Ovid Therapeutics and Metagenomi unveil leadership changes and financial results, highlighting strategic shifts and future growth opportunities in biotech.

Bristol Myers Squibb and Sarah Cannon Research Institute expanded their strategic collaboration, leveraging SCRI’s Accelero model to streamline operations, embed studies within community care settings, and extend cutting-edge oncology therapies to more diverse patient populations.

Following the removal of George Tidmarsh, HHS and FDA has appointed Richard Pazdur, M.D., director of CDER.

In today’s Pharmaceutical Executive Daily, we report on new data showing Wegovy’s potential to reduce liver injury in patients with MASH, Eli Lilly’s latest strategic collaborations in gene therapy, and Novo Nordisk’s decision not to increase its acquisition offer for Metsera following Pfizer’s entry.

Per the FDA's request, HHS is updating hormone therapy labels, removing misleading warnings to empower women in managing menopause and improving their health options.

In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma, the industry’s growing interest in direct-to-patient wholesale models, and the FDA’s expansion of its National Priority Voucher program to accelerate review of critical therapies.

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to advance RNAi-based treatments for metabolic diseases, with the agreements collectively valued at more than $1.6 billion in potential milestone payments.

Metsera finalizes a $10 billion merger with Pfizer after rejecting Novo Nordisk's bids amid legal concerns to ensure shareholder value and regulatory safety.

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly and Novo Nordisk’s plans to bring their leading weight-loss medications to the TrumpRx platform, the State of Texas’ legal move to block Kenvue’s dividend payment, and the FDA approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma.

Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% reduction in disease progression or death.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are transforming pharma’s next frontier in commercial customer engagement.

FDA’s approval of Caplyta as an adjunctive treatment to oral antidepressants for major depressive disorder in adults, expands the drug’s use to a fourth indication following positive Phase III trial results.

Raj Indupuri, CEO, eClinical Solutions, touched on how AI can significantly enhance risk identification and mitigation in clinical trials by enabling integrated, data-driven quality management from protocol design onward.